Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells
Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER−α) in breast cancer cells results in reduced efficacy of endocrine therapy. Here, we investigated the effect of combined tamoxifen and pentadeca...
Saved in:
| Published in | International journal of molecular sciences Vol. 23; no. 19; p. 11340 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel
MDPI AG
01.10.2022
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1422-0067 1661-6596 1422-0067 |
| DOI | 10.3390/ijms231911340 |
Cover
Loading…
| Abstract | Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER−α) in breast cancer cells results in reduced efficacy of endocrine therapy. Here, we investigated the effect of combined tamoxifen and pentadecanoic acid therapy on ER−α−under−expressing breast cancer cells. Drug resistance gene expression patterns were determined by RNA sequencing analysis and in vitro experiments. For the first time, we demonstrate that the combined treatment of pentadecanoic acid, an odd−chain fatty acid, and tamoxifen synergistically suppresses the growth of human breast carcinoma MCF−7 stem cells (MCF−7/SCs), which were found to be tamoxifen−resistant and showed reduced ER−α expression compared with the parental MCF−7 cells. In addition, the combined treatment synergistically induced apoptosis and accumulation of sub−G1 cells and suppressed epithelial−to−mesenchymal transition (EMT). Exposure to this combination induces re−expression of ER−α at the transcriptional and protein levels, along with suppression of critical survival signal pathways, such as ERK1/2, MAPK, EGFR, and mTOR. Collectively, decreased ER−α expression was restored by pentadecanoic acid treatment, resulting in reversal of tamoxifen resistance. Overall, pentadecanoic acid exhibits the potential to enhance the efficacy of endocrine therapy in the treatment of ER−α−under−expressing breast cancer cells. |
|---|---|
| AbstractList | Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER−α) in breast cancer cells results in reduced efficacy of endocrine therapy. Here, we investigated the effect of combined tamoxifen and pentadecanoic acid therapy on ER−α−under−expressing breast cancer cells. Drug resistance gene expression patterns were determined by RNA sequencing analysis and in vitro experiments. For the first time, we demonstrate that the combined treatment of pentadecanoic acid, an odd−chain fatty acid, and tamoxifen synergistically suppresses the growth of human breast carcinoma MCF−7 stem cells (MCF−7/SCs), which were found to be tamoxifen−resistant and showed reduced ER−α expression compared with the parental MCF−7 cells. In addition, the combined treatment synergistically induced apoptosis and accumulation of sub−G1 cells and suppressed epithelial−to−mesenchymal transition (EMT). Exposure to this combination induces re−expression of ER−α at the transcriptional and protein levels, along with suppression of critical survival signal pathways, such as ERK1/2, MAPK, EGFR, and mTOR. Collectively, decreased ER−α expression was restored by pentadecanoic acid treatment, resulting in reversal of tamoxifen resistance. Overall, pentadecanoic acid exhibits the potential to enhance the efficacy of endocrine therapy in the treatment of ER−α−under−expressing breast cancer cells. Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER-α) in breast cancer cells results in reduced efficacy of endocrine therapy. Here, we investigated the effect of combined tamoxifen and pentadecanoic acid therapy on ER-α-under-expressing breast cancer cells. Drug resistance gene expression patterns were determined by RNA sequencing analysis and in vitro experiments. For the first time, we demonstrate that the combined treatment of pentadecanoic acid, an odd-chain fatty acid, and tamoxifen synergistically suppresses the growth of human breast carcinoma MCF-7 stem cells (MCF-7/SCs), which were found to be tamoxifen-resistant and showed reduced ER-α expression compared with the parental MCF-7 cells. In addition, the combined treatment synergistically induced apoptosis and accumulation of sub-G1 cells and suppressed epithelial-to-mesenchymal transition (EMT). Exposure to this combination induces re-expression of ER-α at the transcriptional and protein levels, along with suppression of critical survival signal pathways, such as ERK1/2, MAPK, EGFR, and mTOR. Collectively, decreased ER-α expression was restored by pentadecanoic acid treatment, resulting in reversal of tamoxifen resistance. Overall, pentadecanoic acid exhibits the potential to enhance the efficacy of endocrine therapy in the treatment of ER-α-under-expressing breast cancer cells.Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER-α) in breast cancer cells results in reduced efficacy of endocrine therapy. Here, we investigated the effect of combined tamoxifen and pentadecanoic acid therapy on ER-α-under-expressing breast cancer cells. Drug resistance gene expression patterns were determined by RNA sequencing analysis and in vitro experiments. For the first time, we demonstrate that the combined treatment of pentadecanoic acid, an odd-chain fatty acid, and tamoxifen synergistically suppresses the growth of human breast carcinoma MCF-7 stem cells (MCF-7/SCs), which were found to be tamoxifen-resistant and showed reduced ER-α expression compared with the parental MCF-7 cells. In addition, the combined treatment synergistically induced apoptosis and accumulation of sub-G1 cells and suppressed epithelial-to-mesenchymal transition (EMT). Exposure to this combination induces re-expression of ER-α at the transcriptional and protein levels, along with suppression of critical survival signal pathways, such as ERK1/2, MAPK, EGFR, and mTOR. Collectively, decreased ER-α expression was restored by pentadecanoic acid treatment, resulting in reversal of tamoxifen resistance. Overall, pentadecanoic acid exhibits the potential to enhance the efficacy of endocrine therapy in the treatment of ER-α-under-expressing breast cancer cells. |
| Author | Cho, Somi Kim Truong, Vi Nguyen-Phuong Ediriweera, Meran Keshawa To, Ngoc Bao |
| AuthorAffiliation | 2 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo 008, Sri Lanka or 3 Subtropical−Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Korea 1 Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 63243, Korea 4 Department of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Korea |
| AuthorAffiliation_xml | – name: 2 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Colombo, Colombo 008, Sri Lanka or – name: 4 Department of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Korea – name: 3 Subtropical−Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Korea – name: 1 Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 63243, Korea |
| Author_xml | – sequence: 1 givenname: Ngoc Bao orcidid: 0000-0003-3252-4143 surname: To fullname: To, Ngoc Bao – sequence: 2 givenname: Vi Nguyen-Phuong surname: Truong fullname: Truong, Vi Nguyen-Phuong – sequence: 3 givenname: Meran Keshawa surname: Ediriweera fullname: Ediriweera, Meran Keshawa – sequence: 4 givenname: Somi Kim orcidid: 0000-0002-0980-2005 surname: Cho fullname: Cho, Somi Kim |
| BookMark | eNp1kU1LHTEUhoMofrXL7gPddDOaj5mbm03BDloLSkt7uw6Z5KTNZSaxSa7oP3Ddn-gvMYNSVOgqh5znPLyHc4C2QwyA0DtKjjiX5Nivp8w4lZTylmyhfdoy1hCyENvP6j10kPOaEMZZJ3fRHl_UasEX--jm1DkwJePocB-nwQew-BuEoi0YHaI3-MR4i3WweKWneOMdBLxKoMtUKRzDs-_vkH0uOhjAPuDL_uz-7q84_tHjT5XPBfdzK-EexjG_QTtOjxnePr2H6OfZ6ao_by6-fv7Sn1w0hktWGgmOczsII5kFywThlC1hkKbrwAxUt60DSV0rhOCWcrPsQAgndEcNMUvB-SH6-Oi92gwTWFNDJz2qq-QnnW5V1F697AT_W_2K10p2ghDeVsGHJ0GKfzaQi5p8NnUFHSBusmKCdVRKxrqKvn-FruMmhbreTLVsWZ2zsHmkTIo5J3D_wlCi5puqFzetPH_FG1908XHO68f_TD0AgiCnbw |
| CitedBy_id | crossref_primary_10_1016_j_phrs_2024_107278 crossref_primary_10_3724_abbs_2024054 crossref_primary_10_1186_s13765_024_00860_3 crossref_primary_10_3390_nu15092052 crossref_primary_10_1007_s12032_023_02081_y crossref_primary_10_1038_s41467_024_53144_1 crossref_primary_10_1007_s12032_024_02473_8 crossref_primary_10_1007_s12010_023_04580_0 crossref_primary_10_1042_BSR20240367 crossref_primary_10_1016_j_algal_2025_103949 crossref_primary_10_1186_s12866_025_03747_5 crossref_primary_10_1016_j_drudis_2023_103569 crossref_primary_10_4103_jcrt_jcrt_608_23 crossref_primary_10_1038_s41598_024_51977_w crossref_primary_10_3390_nu15214607 crossref_primary_10_1016_j_ijbiomac_2024_138809 crossref_primary_10_1007_s40495_024_00386_8 |
| Cites_doi | 10.1006/meth.2001.1262 10.1038/sj.onc.1206937 10.1210/me.2007-0293 10.1016/j.semcancer.2009.02.007 10.1038/sj.neo.7900101 10.1186/1476-4598-9-274 10.4103/2153-3539.95452 10.1186/1476-4598-12-9 10.1007/BF01961241 10.1186/bcr2889 10.1172/JCI60534 10.1016/j.drudis.2016.05.015 10.1016/j.bbrc.2016.03.067 10.1038/oncsis.2017.38 10.3322/caac.21660 10.1371/journal.pone.0020610 10.1186/s12918-015-0178-7 10.18632/oncotarget.4037 10.1007/s10911-009-9113-0 10.1016/S0140-6736(85)91385-6 10.4161/epi.23790 10.1007/s002800100294 10.3390/molecules20022425 10.1186/s12935-014-0126-4 10.1016/j.biochi.2021.04.011 10.1038/35021093 10.1093/jmcb/mju019 10.1007/s10549-020-06033-2 10.1158/0008-5472.CAN-09-1947 10.3390/nu12061663 10.1200/JCO.2016.67.1487 10.1158/0008-5472.CAN-13-2020 10.1158/0008-5472.CAN-05-4363 10.1038/sj.bjc.6604269 10.3390/molecules21070965 10.1177/1758834015608993 10.1038/s41419-018-0811-7 10.1158/0008-5472.CAN-08-3458 10.3390/pharmaceutics14050906 10.1210/en.2002-220620 10.1016/j.ctrv.2016.12.001 10.1186/bcr742 10.1046/j.1365-2184.2003.00266.x 10.1677/erc.1.00776 10.1158/1078-0432.CCR-04-0035 10.1016/j.phrs.2009.01.017 10.1074/jbc.M113.489328 10.1038/sj.onc.1207315 10.1158/1078-0432.CCR-07-0587 10.3390/cancers11071028 10.1002/cyto.990130802 10.1038/cddis.2017.154 10.1038/s41598-017-09764-3 10.18632/oncotarget.16440 10.1016/S0140-6736(03)12342-2 10.1093/jnci/87.6.446 10.3892/mmr.2017.6603 10.1097/00001813-199711000-00002 10.1158/1078-0432.CCR-06-1104 10.1016/S1535-6108(02)00061-2 10.4062/biomolther.2012.20.3.256 10.1634/theoncologist.11-8-868 10.1002/ijc.21355 10.1677/joe.0.1650371 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/ijms231911340 |
| DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1422-0067 |
| ExternalDocumentID | PMC9570034 10_3390_ijms231911340 |
| GrantInformation_xml | – fundername: National Research Foundation of Korea (NRF) grantid: 2020R1A2C1004349 – fundername: Basic Science Research Program through NRF; Ministry of Education grantid: 2016R1A6A1A03012862 |
| GroupedDBID | --- 29J 2WC 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 D1I DIK DU5 DWQXO E3Z EBD EBS EJD ESX F5P FRP FYUFA GNUQQ GUQSH GX1 HH5 HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M2O M48 MODMG O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 TUS UKHRP ~8M 3V. 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c392t-9ef33db7c92ded2703128eb9c55ecb1a44fe91f47773d13c85e77f7a51c0c8733 |
| IEDL.DBID | 7X7 |
| ISSN | 1422-0067 1661-6596 |
| IngestDate | Thu Aug 21 18:40:09 EDT 2025 Fri Jul 11 10:59:40 EDT 2025 Fri Jul 25 20:06:35 EDT 2025 Tue Jul 01 03:40:38 EDT 2025 Thu Apr 24 22:58:23 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c392t-9ef33db7c92ded2703128eb9c55ecb1a44fe91f47773d13c85e77f7a51c0c8733 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0980-2005 0000-0003-3252-4143 |
| OpenAccessLink | https://www.proquest.com/docview/2724289574?pq-origsite=%requestingapplication% |
| PMID | 36232636 |
| PQID | 2724289574 |
| PQPubID | 2032341 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9570034 proquest_miscellaneous_2725199225 proquest_journals_2724289574 crossref_primary_10_3390_ijms231911340 crossref_citationtrail_10_3390_ijms231911340 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-01 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel |
| PublicationPlace_xml | – name: Basel |
| PublicationTitle | International journal of molecular sciences |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Chang (ref_31) 2012; 20 Pucci (ref_42) 2000; 2 ref_50 Baylin (ref_60) 2002; 1 Kang (ref_32) 2014; 74 Cuzick (ref_24) 2003; 361 Johnston (ref_9) 1997; 8 Shao (ref_37) 2003; 6 Polyak (ref_35) 2011; 121 Hiscox (ref_43) 2007; 118 Knowlden (ref_58) 2003; 144 Li (ref_62) 2010; 9 ref_17 Roodi (ref_10) 1995; 87 Creighton (ref_51) 2006; 66 Oba (ref_64) 2021; 186 Xie (ref_56) 2012; 27 ref_22 Pusztai (ref_4) 2006; 11 Rugo (ref_6) 2016; 34 Clarke (ref_38) 2003; 22 Brinkman (ref_40) 2009; 14 Ring (ref_8) 2004; 11 ref_29 Bovenzi (ref_13) 2001; 48 Stoica (ref_54) 2000; 165 Dworkin (ref_61) 2009; 19 Kelloff (ref_57) 2006; 12 Holliday (ref_3) 2011; 13 Vermeulen (ref_27) 2003; 36 Li (ref_25) 2017; 16 Darzynkiewicz (ref_28) 1992; 13 Azuma (ref_65) 2009; 69 Livak (ref_67) 2001; 25 Sun (ref_41) 2016; 21 Ediriweera (ref_18) 2021; 186 Jang (ref_14) 2004; 23 Sainsbury (ref_53) 1985; 325 Li (ref_26) 2013; 12 Nobili (ref_15) 2009; 59 Jenkins (ref_16) 2015; 20 Zhang (ref_47) 2017; 8 Keng (ref_66) 2011; 9 Degraffenried (ref_59) 2004; 10 Bianco (ref_34) 2008; 98 Jiang (ref_46) 2014; 6 Asthana (ref_63) 2013; 288 Yang (ref_12) 2001; 61 Ma (ref_19) 2017; 8 Perou (ref_36) 2000; 406 Sung (ref_1) 2021; 71 Reinert (ref_5) 2015; 7 Mitra (ref_30) 2015; 6 Martinelli (ref_33) 2017; 53 ref_45 Benz (ref_55) 1992; 24 Sulaiman (ref_20) 2018; 9 Li (ref_21) 2017; 7 Geng (ref_49) 2016; 473 Hervouet (ref_11) 2013; 8 Bayliss (ref_52) 2007; 13 Jia (ref_2) 2014; 14 Bai (ref_44) 2017; 6 Dhasarathy (ref_48) 2007; 21 Castrellon (ref_39) 2017; 11 Naugler (ref_23) 2012; 3 ref_7 Chou (ref_68) 2010; 70 |
| References_xml | – volume: 25 start-page: 402 year: 2001 ident: ref_67 article-title: Analysis of relative gene expression data using real−time quantitative PCR and the 2(−Delta Delta C(T)) Method publication-title: Methods doi: 10.1006/meth.2001.1262 – volume: 22 start-page: 7316 year: 2003 ident: ref_38 article-title: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling publication-title: Oncogene doi: 10.1038/sj.onc.1206937 – volume: 21 start-page: 2907 year: 2007 ident: ref_48 article-title: The Transcription Factor Snail Mediates Epithelial to Mesenchymal Transitions by Repression of Estrogen Receptor−α publication-title: Mol. Endocrinol. doi: 10.1210/me.2007-0293 – volume: 19 start-page: 165 year: 2009 ident: ref_61 article-title: Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2009.02.007 – volume: 2 start-page: 291 year: 2000 ident: ref_42 article-title: Cell Cycle and Apoptosis publication-title: Neoplasia doi: 10.1038/sj.neo.7900101 – volume: 9 start-page: 274 year: 2010 ident: ref_62 article-title: Synergistic epigenetic reactivation of estrogen receptor−α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα−negative breast cancer cells publication-title: Mol. Cancer doi: 10.1186/1476-4598-9-274 – volume: 3 start-page: 19 year: 2012 ident: ref_23 article-title: Estrogen receptor testing and 10−year mortality from breast cancer: A model for determining testing strategy publication-title: J. Pathol. Inform. doi: 10.4103/2153-3539.95452 – volume: 12 start-page: 9 year: 2013 ident: ref_26 article-title: Epigenetic reactivation of estrogen receptor−α (ERα) by genistein enhances hormonal therapy sensitivity in ERα−negative breast cancer publication-title: Mol. Cancer doi: 10.1186/1476-4598-12-9 – volume: 24 start-page: 85 year: 1992 ident: ref_55 article-title: Estrogen−dependent, tamoxifen−resistant tumorigenic growth of MCF−7 cells transfected with HER2/neu publication-title: Breast Cancer Res. Treat. doi: 10.1007/BF01961241 – volume: 13 start-page: 215 year: 2011 ident: ref_3 article-title: Choosing the right cell line for breast cancer research publication-title: Breast Cancer Res. doi: 10.1186/bcr2889 – volume: 121 start-page: 3786 year: 2011 ident: ref_35 article-title: Heterogeneity in breast cancer publication-title: J. Clin. Investig. doi: 10.1172/JCI60534 – volume: 21 start-page: 1189 year: 2016 ident: ref_41 article-title: Drug combination therapy increases successful drug repositioning publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2016.05.015 – volume: 473 start-page: 147 year: 2016 ident: ref_49 article-title: Curcumin suppresses 4−hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2016.03.067 – volume: 6 start-page: e330 year: 2017 ident: ref_44 article-title: The zinc−finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine−specific demethylase 1 in human breast cancer publication-title: Oncogenesis doi: 10.1038/oncsis.2017.38 – volume: 71 start-page: 209 year: 2021 ident: ref_1 article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 11 start-page: 323 year: 2017 ident: ref_39 article-title: Novel strategies to improve the endocrine therapy of breast cancer publication-title: Oncol. Rev. – ident: ref_45 doi: 10.1371/journal.pone.0020610 – ident: ref_50 doi: 10.1186/s12918-015-0178-7 – volume: 6 start-page: 10697 year: 2015 ident: ref_30 article-title: EMT, CTCs and CSCs in tumor relapse and drug−resistance publication-title: Oncotarget doi: 10.18632/oncotarget.4037 – volume: 14 start-page: 67 year: 2009 ident: ref_40 article-title: ER Re−expression and Re−sensitization to Endocrine Therapies in ER−negative Breast Cancers publication-title: J. Mammary Gland Biol. Neoplasia doi: 10.1007/s10911-009-9113-0 – volume: 325 start-page: 364 year: 1985 ident: ref_53 article-title: EPIDERMAL−GROWTH−FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER publication-title: Lancet doi: 10.1016/S0140-6736(85)91385-6 – volume: 8 start-page: 237 year: 2013 ident: ref_11 article-title: Epigenetic regulation of estrogen signaling in breast cancer publication-title: Epigenetics doi: 10.4161/epi.23790 – volume: 48 start-page: 71 year: 2001 ident: ref_13 article-title: Antineoplastic action of 5−aza−2′−deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s002800100294 – volume: 20 start-page: 2425 year: 2015 ident: ref_16 article-title: A Review of Odd−Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease publication-title: Molecules doi: 10.3390/molecules20022425 – volume: 14 start-page: 126 year: 2014 ident: ref_2 article-title: The differential susceptibilities of MCF−7 and MDA−MB−231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt−SKP2−Cip/Kips pathway publication-title: Cancer Cell Int. doi: 10.1186/s12935-014-0126-4 – volume: 186 start-page: 147 year: 2021 ident: ref_18 article-title: Odd−chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors publication-title: Biochimie doi: 10.1016/j.biochi.2021.04.011 – volume: 9 start-page: 13 year: 2011 ident: ref_66 article-title: Isolation and comparison of tumorigenicity of different cell populations from the MCF−7 breast cancer cell line based on CD44 and CD24 markers publication-title: Vietnam. J. Sci. Technol. – volume: 406 start-page: 747 year: 2000 ident: ref_36 article-title: Molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/35021093 – volume: 6 start-page: 352 year: 2014 ident: ref_46 article-title: Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR–ERK independent of epithelial–mesenchymal transition publication-title: J. Mol. Cell Biol. doi: 10.1093/jmcb/mju019 – volume: 186 start-page: 37 year: 2021 ident: ref_64 article-title: −I. HDAC6 inhibition enhances the anti−tumor effect of eribulin through tubulin acetylation in triple−negative breast cancer cells publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-020-06033-2 – volume: 70 start-page: 440 year: 2010 ident: ref_68 article-title: Drug combination studies and their synergy quantification using the Chou−Talalay method publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-1947 – ident: ref_17 doi: 10.3390/nu12061663 – volume: 34 start-page: 3069 year: 2016 ident: ref_6 article-title: Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.67.1487 – volume: 74 start-page: 1484 year: 2014 ident: ref_32 article-title: Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis−associated protein 1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-2020 – volume: 66 start-page: 3903 year: 2006 ident: ref_51 article-title: Activation of mitogen−activated protein kinase in estrogen receptor α–positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α–negative human breast tumors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-4363 – volume: 98 start-page: 923 year: 2008 ident: ref_34 article-title: Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti−EGFR drugs publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6604269 – ident: ref_29 doi: 10.3390/molecules21070965 – volume: 7 start-page: 304 year: 2015 ident: ref_5 article-title: Optimal management of hormone receptor positive metastatic breast cancer in 2016 publication-title: Ther. Adv. Med Oncol. doi: 10.1177/1758834015608993 – volume: 27 start-page: 1879 year: 2012 ident: ref_56 article-title: Role of PKC−ERK signaling in tamoxifen−induced apoptosis and tamoxifen resistance in human breast cancer cells publication-title: Oncol. Rep. – volume: 9 start-page: 815 year: 2018 ident: ref_20 article-title: Co−inhibition of mTORC1, HDAC and ESR1α retards the growth of triple−negative breast cancer and suppresses cancer stem cells publication-title: Cell Death Dis. doi: 10.1038/s41419-018-0811-7 – volume: 69 start-page: 2935 year: 2009 ident: ref_65 article-title: Association of Estrogen Receptor α and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-3458 – ident: ref_22 doi: 10.3390/pharmaceutics14050906 – volume: 144 start-page: 1032 year: 2003 ident: ref_58 article-title: Elevated levels of epidermal growth factor receptor/c−erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen−resistant MCF−7 cells publication-title: Endocrinology doi: 10.1210/en.2002-220620 – volume: 53 start-page: 61 year: 2017 ident: ref_33 article-title: Cancer resistance to therapies against the EGFR−RAS−RAF pathway: The role of MEK publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2016.12.001 – volume: 6 start-page: 39 year: 2003 ident: ref_37 article-title: Advances in estrogen receptor biology: Prospects for improvements in targeted breast cancer therapy publication-title: Breast Cancer Res. doi: 10.1186/bcr742 – volume: 36 start-page: 131 year: 2003 ident: ref_27 article-title: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer publication-title: Cell Prolif. doi: 10.1046/j.1365-2184.2003.00266.x – volume: 11 start-page: 643 year: 2004 ident: ref_8 article-title: Mechanisms of tamoxifen resistance publication-title: Endocr.−Relat. Cancer doi: 10.1677/erc.1.00776 – volume: 10 start-page: 8059 year: 2004 ident: ref_59 article-title: Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-04-0035 – volume: 59 start-page: 365 year: 2009 ident: ref_15 article-title: Natural compounds for cancer treatment and prevention publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2009.01.017 – volume: 288 start-page: 22516 year: 2013 ident: ref_63 article-title: Inhibition of HDAC6 Deacetylase Activity Increases Its Binding with Microtubules and Suppresses Microtubule Dynamic Instability in MCF−7 Cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M113.489328 – volume: 23 start-page: 1724 year: 2004 ident: ref_14 article-title: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α−negative breast cancer cells to tamoxifen publication-title: Oncogene doi: 10.1038/sj.onc.1207315 – volume: 13 start-page: 7029 year: 2007 ident: ref_52 article-title: Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-0587 – ident: ref_7 doi: 10.3390/cancers11071028 – volume: 13 start-page: 795 year: 1992 ident: ref_28 article-title: Features of apoptotic cells measured by flow cytometry publication-title: Cytometry doi: 10.1002/cyto.990130802 – volume: 8 start-page: e2732 year: 2017 ident: ref_47 article-title: ZEB1 induces ER−α promoter hypermethylation and confers antiestrogen resistance in breast cancer publication-title: Cell Death Dis. doi: 10.1038/cddis.2017.154 – volume: 7 start-page: 9345 year: 2017 ident: ref_21 article-title: Combinatorial bioactive botanicals re−sensitize tamoxifen treatment in ER−negative breast cancer via epigenetic reactivation of ERα expression publication-title: Sci. Rep. doi: 10.1038/s41598-017-09764-3 – volume: 8 start-page: 29328 year: 2017 ident: ref_19 article-title: Z−ligustilide restores tamoxifen sensitivity of ERα negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERα publication-title: Oncotarget doi: 10.18632/oncotarget.16440 – volume: 61 start-page: 7025 year: 2001 ident: ref_12 article-title: Synergistic activation of functional estrogen receptor (ER)−α by DNA methyltransferase and histone deacetylase inhibition in human ER−α−negative breast cancer cells publication-title: Cancer Res. – volume: 361 start-page: 296 year: 2003 ident: ref_24 article-title: Overview of the main outcomes in breast−cancer prevention trials publication-title: Lancet doi: 10.1016/S0140-6736(03)12342-2 – volume: 87 start-page: 446 year: 1995 ident: ref_10 article-title: Estrogen Receptor Gene Analysis in Estrogen Receptor−Positive and Receptor−Negative Primary Breast Cancer publication-title: JNCI J. Natl. Cancer Inst. doi: 10.1093/jnci/87.6.446 – volume: 16 start-page: 478 year: 2017 ident: ref_25 article-title: Tamoxifen promotes apoptosis and inhibits invasion in estrogen−positive breast cancer MCF−7 cells publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2017.6603 – volume: 8 start-page: 911 year: 1997 ident: ref_9 article-title: Acquired tamoxifen resistance in human breast cancer–potential mechanisms and clinical implications publication-title: Anti−Cancer Drugs doi: 10.1097/00001813-199711000-00002 – volume: 12 start-page: 3661 year: 2006 ident: ref_57 article-title: Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1104 – volume: 1 start-page: 299 year: 2002 ident: ref_60 article-title: Altered methylation patterns in cancer cell genomes: Cause or consequence? publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00061-2 – volume: 20 start-page: 256 year: 2012 ident: ref_31 article-title: Tamoxifen resistance in breast cancer publication-title: Biomol. Ther. doi: 10.4062/biomolther.2012.20.3.256 – volume: 11 start-page: 868 year: 2006 ident: ref_4 article-title: Molecular Classification of Breast Cancer: Limitations and Potential publication-title: Oncologist doi: 10.1634/theoncologist.11-8-868 – volume: 118 start-page: 290 year: 2007 ident: ref_43 article-title: Tamoxifen resistance in MCF7 cells promotes EMT−like behaviour and involves modulation of β−catenin phosphorylation publication-title: Int. J. Cancer doi: 10.1002/ijc.21355 – volume: 165 start-page: 371 year: 2000 ident: ref_54 article-title: Regulation of estrogen receptor−alpha gene expression by epidermal growth factor publication-title: J. Endocrinol. doi: 10.1677/joe.0.1650371 |
| SSID | ssj0023259 |
| Score | 2.4710379 |
| Snippet | Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER−α)... Estrogen receptors are indicators of breast cancer adaptability to endocrine therapies, such as tamoxifen. Deficiency or absence of estrogen receptor α (ER-α)... |
| SourceID | pubmedcentral proquest crossref |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 11340 |
| SubjectTerms | Apoptosis Breast cancer Cancer therapies Cell cycle Cytotoxicity Drug resistance Endocrine therapy Epigenetics Estrogens Fatty acids Gene expression Kinases Proteins |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fi9NAEF_kDsEX8fyD1VNWEJ-M1yS73eyDyBksh1ARbeHeQjo7i5HeRpse9L6Bz37E-yQ3k7S9C_55zcyyZHaH-Q0z-xshXiKM0CptIywxjZQDRS41dJGfE9b3ydAk7SOxyafRyUx9PNWn15RCGwM2f03teJ7UbLl4s_558Y4c_i1nnJSyH1XfzxqCKeS2qaLsfZ-CkmEfnahdQYFwQzs3LaZwFI20HXV0m38u74ena8zZ75i8EYLG98TdDXaUx91hH4hbGO6L2900yYsHYt0xETey9pLcnFJedPIz94Y7JAPWFchjqJwsg5PT8qxeVx6DnG47zWUdbnz-gg0jS7oSsgpyko8vf_02R19z-Z672FcyZ9FS5rhYNA_FbPxhmp9Em8EKERAcWkUWfcq8ymAThy5hCvskw7kFrRHmcamURxt7ZYxJXZxCptEYb0odwxAyk6aPxF6oAz4W0mgF9HOEizKvEBgvDGPH5WxwMUA8EK-39ixgwzrOwy8WBWUfbP6iZ_6BeLVT_9HRbfxL8XB7OMX20hSJIcCRWW3UQLzYiclfuAhSBqzPWx3NLbeJHgjTO9Tdhsy43ZeE6lvLvG15GkCqnvx_86fiTsKPJNqWv0Oxt1qe4zOCLqv58_ZSXgGCXO79 priority: 102 providerName: Scholars Portal |
| Title | Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells |
| URI | https://www.proquest.com/docview/2724289574 https://www.proquest.com/docview/2725199225 https://pubmed.ncbi.nlm.nih.gov/PMC9570034 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Na9wwEBVtQqGX0k-6bbKoUHqq2bUlraxTSUy2obAhpBvYm_FKI-qwkdN4A-k_6Lk_sb8kM7b369BedLAEwpJG80Z6esPYR7AjMFKZCAoQkXRWokkNXeTniPV9MtRJ80hscjY6vZTfZmrWHbjVHa1ytSc2G7WrLJ2RDxKNziQ1SssvNz8jyhpFt6tdCo3HbJ-ky4jSpWebgEskTbK0GH1QNFJm1GpsCgzzB-XVdY3QBk1d0LnHtk_aAM1dmuSW3xk_Z886wMiP2hl-wR5BeMmetCkkf71i9638cM0rz9G2Mc4Fx8-JEO4AR60qLT-ypeNFcHxaXFf3pYfApyt6Oa_C1ucLqAlO4jrgZeCTbPz39x89-J7xY6KuL3lGVbc8g8Wifs0uxyfT7DTqsilEFjHQMjLgBYkpW5M4cAnp1icpzI1VCuw8LqT0YGIvtdbCxcKmCrT2ulCxHdpUC_GG7YUqwFvGtZIWfw7BUOolWAIJw9jRHbZ1sbVxj31ejWduO6lxynixyDHkoOHPd4a_xz6tm9-0Ghv_aniwmpy8M7U63yyMHvuwrkYjoZuPIkB117RRxLNNVI_pnUldd0gy27s1ofzRyG0bSgEg5Lv_d_6ePU3oZUTD8ztge8vbOzhEvLKc95tFiWU6_tpn-8cnZ-cXffIgCsuJTB8AbpPwcA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELaqIgQXxK9YaIuRgBPRJo69jg8VKoHVlnYrBFtpbyFrT9SgbVKarWjfgHMfhIfiSZhJNvtzgFuvsSUr4_n5xh5_w9grsD0wUhkPUgg96axEk_Kdl00Q62fC16J-JDY86g2O5aexGm-w3-1bGCqrbH1i7ahdaemMvCs0BpPIKC3fnf3wqGsU3a62LTQatTiAq5-YslW7-x9wf18L0f84igfevKuAZxELzDwDWUikwtYIB04Qf7uIYGKsUmAnQSplBibIpNY6dEFoIwVaZzpVgfVtpOkAFF3-LQy8PlmUHi8TvFDUzdkCjHleT5lew-kZhsbv5t9PK4RS6FpCOmdZjYFLYLtelrkS5_r32b05QOV7jUY9YBtQPGS3m5aVV4_YZUN3XPEy4-hLMK8Gxz9TAboD3KUyt3zP5o6nheOj9LS8zDMo-KgtZ-dlsfL5C1QEX1HveF7wYdz_8-tad7_G_D2Vys94TEPnPIbptHrMjm9Ezk_YZlEW8JRxraTFn0PwFWUSLIESP3B0Z25dYG3QYW9beSZ2Tm1OHTamCaY4JP5kTfwd9mYx_azh9PjXxK12c5K5aVfJUhE77OViGI2SblrSAsqLeo6iul6hOkyvbepiQaL1Xh8p8pOa3ttQy4FQPvv_4i_YncFoeJgc7h8dPGd3Bb3KqGsMt9jm7PwCthErzSY7tYJy9u2mLeIvv7opaA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIhAXxFMsFDAScCLajR_r5IBQSVm1lFYVbKW9haw9FkHbpDRb0f4Dzvwcfg6_hJk89nGAW6-xJSvjeXxjf55h7AXYIcRKxwFkIAPlrEKTGrjATxHrezEwon4kdnA43D1WHyZ6ssF-d29hiFbZ-cTaUbvS0hl5XxgMJlGsjer7lhZxtDN6e_o9oA5SdNPatdNoVGQfLn9g-la92dvBvX4pxOj9ONkN2g4DgUVcMA9i8JIKDNtYOHCCarmLCKax1RrsNMyU8hCHXhljpAuljTQY402mQzuwkaHDUHT_14zUIdmYmSyTPSnqRm0hxr9gqONhU99TynjQz7-dVAir0M1IOnNZjYdLkLtO0VyJeaPb7FYLVvl2o1132AYUd9n1pn3l5T120ZQ-rnjpOfoVzLHB8SMiozvAHStzy7dt7nhWOD7OTsqL3EPBxx21nZfFyudPUBGURR3kecEPktGfn79M_3PC3xFtfs4TGjrjCcxm1X12fCVyfsA2i7KAh4wbrSz-HAKxyCuwBFAGoaP7c-tCa8Mee93JM7VtmXPqtjFLMd0h8adr4u-xV4vpp019j39N3Oo2J23NvEqXStljzxfDaKB065IVUJ7XczRxfIXuMbO2qYsFqcT3-kiRf61LfcfUfkCqR_9f_Bm7gbaQftw73H_Mbgp6oFHTDbfY5vzsHJ4gbJpPn9b6ydmXqzaIv07eLZ4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+Combined+Pentadecanoic+Acid+and+Tamoxifen+Treatment+on+Tamoxifen+Resistance+in+MCF%E2%88%927%2FSC+Breast+Cancer+Cells&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Ngoc+Bao+To&rft.au=Vi+Nguyen-Phuong+Truong&rft.au=Meran+Keshawa+Ediriweera&rft.au=Somi+Kim+Cho&rft.date=2022-10-01&rft.pub=MDPI+AG&rft.issn=1661-6596&rft.eissn=1422-0067&rft.volume=23&rft.issue=19&rft.spage=11340&rft_id=info:doi/10.3390%2Fijms231911340&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |